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1. Membrane fusion 
1. Membrane fusion 
 
1.1 Mechanism of membrane fusion 
 
Membrane fusion is an important part of all fundamental biological events under 
normal and pathological conditions and a complex process, in which two 
membranes merge together. A protein machinery controls membrane fusion in 
exo- and endocytosis, in intracellular trafficking, in enveloped virus infections and 
in many other lipid membrane related reactions. The prevailing mechanism of the 




Figure 1.1.  Fusion through a hemifusion pathway of the lipid bilayer. a) Pre-fusion contact. b) A point-like 
membrane protrusion (minimizes the energy of the hydration repulsion between the proximal leaflets of the 
membranes coming into immediate contact). c) A hemifusion stalk. d) Stalk expansion yields the hemifusion 




The fusion through a hemifusion pathway of membrane fusion (Figure 1.1) was first 
investigated theoretically and confirmed by experiments with merging of artificial 
protein-free bilayers,[5-7] and then found for viral,[2] intracellular,[8-11] and cell 
fusion.[12] The established mechanism involves hemifusion, a stalk-like connection 
between the outer membrane leaflets where the inner leaflets and the aqueous 
inner contents remain distinct (Figure 1.1, c). The hemifusion stage is then followed 
by fusion pore openning in order to complete the fusion process (Figure 1.1, e). 
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Two important types of intermediates have been characterized: hemifusion 
structures and fusion pores. Hemifusion between two vesicles has usually been 
defined as lipid mixing without content mixing or as limited mixing within the outer 
leaflet and the inner leaflet not merging.[11, 13, 14] 
Some electrophysiological measurements provided evidence for involvement of 
hemifusion intermediates.[6,15] A hemifusion connection is often a transient 
structure that either dissociates to yield two separated membranes or transforms to 
a fusion pore.[3, 15] The latter one is a connection between merging membranes 
involving both, outer and inner leaflets (Figure 1.1, e). Fusion pore formation 
provides aqueous connections between the initially separated parts of the 
membranes. Various electrophysiological approaches and fluorescence assays, 
which monitor the mixing between aqueous contents and/or the lipids of the inner 
leaflets, have been employed for investigating fusion pore formation and 
expansion.[6,7,15] 
The fusion between biological membranes is always mediated by different 
membrane-bound proteins. Notably, the mechanisms of natural membrane fusion 
processes mediated by viral, intracellular as well as developmental fusogens 
appear to be very similar.[16] 
 
1.2 Intracellular fusion 
 
The intracellular transport between plasma membrane and different organelles in 
eukaryotic cells involves vesicular intermediates that separate donor compartments 
and fuse with acceptor compartments. Vesicle budding and transferred cargo 
selection are known to be mediated by protein coats,[17, 18] while vesicle targeting 
and fusion are controlled by specific fusogenic proteins (Figure 1.2).[19] The 
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In 1993, an important discovery concerning the mechanism of intracellular fusion 
was found; both, the intracellular transport (targeting and fusion steps) and the 
synaptic transmission are mediated by the same proteins.[21, 22] These so-called 
SNARE (Soluble N-ethylmaleimide-Sensitive Factor Attachment Protein Receptor) 
proteins turned out to mediate all transport steps of the secretory pathway in 
membrane fusion. However, the fusion events in mitochondria and peroxisomes 
involve proteins, which are completely different from the SNARE proteins.[23-25] The 
SNARE superfamily of small proteins includes 24 known members in yeast and 35 
in mammals.[26] A simple domain structure and the presence of an evolutionarily 
conserved SNARE motif (60–70 amino acids in heptad repeats) are characterizing 
all SNARE proteins. Most SNAREs have a single transmembrane domain at their 
C-termini, which is connected to the SNARE motif by a short linker. N-Terminal 
domains are not conserved and their structure considerably varies among diverse 
subgroups of SNAREs.[27,28] 
Remarkable is the fact, that different sets of SNAREs from two opposing 
membranes were found to associate into complexes that are subsequently 
disassembled by the NSF protein.[29] Originally, these proteins were designated as 
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v-SNAREs (vesicle-membrane SNAREs) and t-SNAREs (target-membrane 
SNAREs).[29] The formation of a complex from these proteins, typically containing 
two t-SNAREs and one v-SNARE protein, is mediated by the SNARE motifs, which 
form a parallel four-helix coiled-coil structure termed SNARE complex.[30] The 




Figure 1.3. The SNARE conformational cycle during vesicle docking and fusion. Q-SNAREs, which are 
organized in clusters (top left), assemble into acceptor complexes, and this assembly process might require 
SM (Sec1/Munc18-related) proteins. Acceptor complexes interact with the vesicular R-SNAREs through the N-
terminal end of the SNARE motifs, and this nucleates the formation of a four-helical trans-complex. Trans-
complexes proceed from a loose state (in which only the N-terminal portion of the SNARE motifs are ‘zipped 
up’) to a tight state (in which the zippering process is mostly completed), and this is followed by the opening of 
the fusion pore. In regulated exocytosis, these transition states are controlled by late regulatory proteins that 
include complexins (small proteins that bind to the surface of SNARE complexes) and synaptotagmin (which is 
activated by an influx of calcium). During fusion, the strained trans-complex relaxes into a cis-configuration. 
Cis-complexes are disassembled by the AAA+ (ATPases associated with various cellular activities) protein 






1. Membrane fusion 
The crystal structures of two evolutionary distantly related SNARE complexes 
display a remarkable structural conservation.[30, 31] Thus, the core complex always 
contains 16 stacked layers of interacting side chains. These layers are all largely 
hydrophobic, except for a central “0” layer that contains three highly conserved 
glutamine (Q) residues and one highly conserved arginine (R) residue (Figure 1.4). 
The comparison of the primary sequences of closely or only distantly related 




Figure 1.4. Scheme of a neuronal SNARE complex and skeleton diagram indicating the positions of the 
corresponding layers (numbered) in interacting side chains. The complex contains the SNARE motifs of 
syntaxin-1A (Qa-, depicted red), SNAP-25 (Qb- and Qc-, green) and VAMP/synaptobrevin (R-, blue).[32] 
 
The characteristic motifs building SNARE structures are designated as Qa-, Qb-, 
Qc- and R- SNAREs (Figure 1.3).  Functional SNARE complexes that drive 
membrane fusion are hetero-oligomeric, parallel four-helix bundles, and each 
bundle is invariant, requiring one of each of the Qa-, Qb-, Qc- and R-SNAREs. A 
phylogenetic analysis of SNARE sequences from S. cerevisiae, A. thaliana and 
mammals has been shown that these four SNARE subfamilies are highly 
conserved and diverged early in eukaryotic evolution.[26,27]  
Due to their amphiphilic nature, SNARE motifs can also associate in other 
combinations that result in helical bundles that are less stable than core 
complexes. Particularly noteworthy are the complexes that are formed by the 
neuronal SNAREs. These include a Qaaaa complex (an antiparallel four-helix 
bundle)[127], a Qabab complex (a parallel four-helix bundle)[128], a Qaabc complex 
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(a parallel four-helix bundle with some disordered regions)[129,130] and, surprisingly, 
an antiparallel QabcR complex.[131,132] These complexes might not have the correct 
membrane topology or they might not contribute sufficient energy to drive 
membrane fusion. They probably represent ‘off-pathway’ reactions.[19]  
The region surrounding the boundary membrane, termed as “vertex ring”, initially 
becomes highly enriched with the fusion required Rab, Rab-effector complex, 
SNAREs, and “regulatory lipids” such as ergosterol and phosphoinositides.[33-35] 
Subsequently, fusion occurs around the “vertex ring”, joining the two boundary 
membranes and yielding a luminal vesicle within the larger fused organelle. After 
“vertex ring” formation, trans-SNARE complexes assembles and the additional 
regulatory proteins bind to trans-SNARE (Figure 1.3).[19] The later include SM-
proteins and other proteins or domains that bind to Ca2+, to lipids or to SNAREs.[36] 
SNARE proteins (usually R- and Qa-) have transmembrane anchors in opposite 
bilayers (R- in the vesicle and Qa- in the target membrane, respectively). Thus, the 
formation of a trans-SNARE complex by “zippering” starting from the N-terminal 
end to its C-terminal membrane anchor clamps the opposite membranes together 
and drives bilayer distortion, first hemifusion, and then, complete fusion of 
membranes.[37] The full fusion converts trans-SNARE complexes to the 
corresponding post-fusion cis-SNARE complexes in which all SNAREs reside 
together in the resulting fused membrane.[19] In the final step, α-SNAP displaces 
other SNARE-bound proteins and prepares the cis-SNARE complex for the ATP-
dependent disassembly by NSF.[38, 39] 
The mechanism of membrane fusion has been extensively investigated to unravel 
the aspects of this important life process. However, the specific physical forces and 
molecular mechanisms governing this process still remain unclear or not 
completely understood. Therefore, further studying of the whole fusion process as 
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1.3 Model systems for membrane fusion 
 
To shed light on the role of membrane apposition and the transmembrane domains 
of fusion proteins, fusion experiments have been carried out using vesicles 
reconstituted with fusion proteins.[40] In addition, artificial model systems have been 
created that mimic the function of SNAREs in fusion reactions in vitro.[41–47] Artificial 
SNARE analogues have the advantage of simplifying the complex SNARE 
assembly reaction such that systematic structural variations and system 
compositions can be used to study the influence of each segment on the fusion 
process. 
SNARE analogues membrane fusion was successfully mediated by coiled-coil 
peptides,[47-49] DNA double strand formation,[45,46] aminoethylglycine peptide nucleic 
acids (aeg PNA),[50] boronic acid/cis-diol,[51,52] hydrogen bonding between cyanuric 
acid and melamine,[43,44] and vancomycin/D-Ala-D-Ala recognition.[42,53]  
Some similar fusogenic systems based on recognition of nucleo bases with a 
phospholipid chain as an anchor in membrane were designed.[54] The influence of 
DNA binding geometry on the fusion probability was investigated. Thus, it was 
found that fusion events occured only when different DNAs were coupled to the 
lipid anchors with 5’- or 3’-ends, forming complementary duplexes (Figure 1.5). On 
the contrary, in case all complementary DNAs were bound with the 5’-end, fusion 
was not observed, because the resulting duplex acted as a spacer between the 
membrane surfaces, inhibiting close contact between these surfaces necessary for 
a fusion event. Notably, the geometry of DNA/lipid conjugates containing 5’- and 3’-
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Figure 1.5. Schematic illustration of the binding of a vesicle to a planar membrane mediated either by SNARE 




KROS and coworkers presented a SNARE model system based on a coiled-coil 
forming α-peptide recognition motif.[47] A complementary pair of coiled-coil forming 
peptides, G(EIAALEK)3 (E3) and WWG(KIAALKE)3 (K3), interacting in parallel 
orientation was used as SNARE recognition motif (Figure 1.6). The peptides were 
conjugated with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine lipid (DOPE) 
through a PEG12 linker, followed by incorporating this lipid into membrane bilayer. 
The anchored peptides E3 and K3 in the vesicles form a stable heterodimer 
complex, which bring two membranes in close proximity leading to fusion. The 
elongation of the coiled-coil motif to four repeating units (E4 and K4) increased the 
rate of fusion.[47] Furthermore, more hydrophobic anchors such as cholesterol and 
DOPE increased the fusion rate while less hydrophobic linkers such as palmitoleic 
acid, decanoic acid, and adamantine carboxylic acids decreased the fusion 
efficiency.[47] This study suggests that the lipid anchor and the efficient 
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Figure 1.6. a) E and K coiled-coil domains anchored to DOPE lipid through a PEG12 linker. b) Schematic 




The coiled-coil recognition were proved to be an excellent replacement for the 
SNARE motif in terms of achieving leakage-free efficient and full fusion of the 
vesicles with content mixing. Therefore, the coiled-coil recognition motif has been 
further investigated as SNARE recognition motif anchored to TMDs and linkers of 
native SNARE proteins (Figure 1.7) [48]. Thus, coiled-coil forming helices of E3 and 
K3 were directly linked to the TMDs of VAMP2 and syntaxin-1A. Lipid mixing and 
content mixing assays showed full fusion of the vesicles bearing TMD VAMP2 E3 
with the vesicles carrying TMD syntaxin K3.  
 
 
Figure 1.7. SNARE fusion model system based on native TMD and linker domains of syntaxin (blue helix) 
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Peptide nucleic acids or PNA recognition has been used as SNARE motif analog 
because antiparallel and parallel duplexes can be formed dependent on 
nucleobase sequence (Figure 1.8).[50] PNA sequences were chosen that ensure 
duplex formation at room temperature and provide orientation of the connected 
TMDs on opposite sides (antiparallel orientation, PNA1 gtagatcact and PNA2 
agtgatctac) or on the same side of the recognition complex (parallel orientation, 
PNA1 and PNA3 catctagtga). For both combinations, lipid mixing between reacting 
vesicles can be observed. However, in accordance with the native SNARE 
complex, fusion initiated by parallel PNA strand recognition is more efficient than 
by antiparallel PNA duplex formation. Because the PNA recognition motif is quite 
small, spacing between opposed TMDs and vesicle membranes is not sufficient to 
suppress lipid exchange even in case of the antiparallel recognition motif. Content 
mixing fusion assays with the PNA-based model system reveals that a significant 
amount of vesicles is arrested in hemifusion stage preceding the full membrane 
fusion only providing outer leaflet lipid mixing. 
The roll of transmembrane domain has been investigated using aeg-PNA peptides. 
The results showed that effective fusion events take place only if full-length TMDs 
(SyxTMD and SbTMD) pull together the outer and the inner leaflets of both 
merging vesicle membranes. The fusion efficiency decreases significantly when 
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Figure 1.8. Simplified PNA/peptide models with complementary parallel strand orientation of PNA1 (blue) and 
PNA3 (red). (A) Model system containing a part of Sb-TMD (Syb, violet). (B) Model system containing a part of 
Syx-TMD (Sx, orange). (C)  Model system containing TMD parts of syntaxin-1A and synabtobrevin 2.
[50] 
 
The transmembrane anchors in the native SNARE complex are linked at the same 
side of the SNARE recognition motif corresponding to a parallel orientation of 
recognizing oligomers. The mechanistic requirement of this parallel organization for 
vesicle fusion was investigated using DNA, aeg-PNA and the coiled-coil peptides 
clearly indicate that membrane anchors attached to opposite sides of the 
recognition motif (antiparallel orientation) inhibit or at least reduce fusogenicity. 
Nevertheless, vesicle fusion can be obtained also with antiparallel attached TMDs 
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1.4. Goals of this Study 
 
The study of the relevant literature concerning the known mechanisms of 
membrane fusion and previously employed artificial fusogens indicated, that further 
development of the new model systems for membrane fusion and improvement of 
already available ones, is a challenging task. The usage of a well defined 
recognition unit with a special topology instead of native SNARE motif would 
potentially clarify the molecular mechanisms governing membrane fusion and open 
new attractive ways for drug delivery. The nucleobase-functionalized β-peptides or 
β-PNA are potential candidate to use as SNARE recognition units. 
Thus, the main goal of this study is to develop novel model systems for specific 
membrane fusion and distance regulated vesicle fusion based on β-PNA. The 
following aspects are to be addressed: 
 synthesis of the corresponding model systems for membrane fusion; 
 investigation of the behavior of synthesized fusogens in membranes; 














2. Bases and design of the β-peptide 




A foldamer is defined as an oligomer that folds into a conformationally ordered 
state in solution, a structure that is stabilized by a collection of noncovalent 
interactions between nonadjacent monomeric units.[56] There are two major types 
of foldamers: single-stranded foldamers and multiple-stranded foldamers. 
Recently, several peptidomimetic foldamers have attracted a lot of attention 
because of their unique conformations and interesting bioactivities.[56] The family of 
β-peptides is a major class of foldamers, studied over the years due to their unique 
folding behavior in solution.[55,57] In comparison to α-peptides, β-peptides are more 
flexible because of the presence of an additional methylene group. β-Peptides 
have received considerable attention due to their structural diversities.[55, 57-59]  At 
least 15-20 α-amino acids are required to form a stable α-helical secondary 
structure. Considering the higher conformational flexibility of β-peptides, one might 
expect that even a longer backbone would be required to obtain a stable helical 
secondary structure. However, it has been shown that β-peptides composed of as 
few as six β-amino acid residues form surprisingly stable helices.[57] The β-peptide 
oligomers are resistant towards enzymatic degradation and have little tendency for 
the H/D exchange of the central amide protons.[60] β-Peptides are shown also to 
have versatile biological activity.[61] Furthermore, it was shown that β-amino acids 
have a significant potential to function as powerful peptidomimetics.[62] In the recent 
years, several research groups have contributed in this field and have concluded 
that short β-peptide oligomers form stable helices in solution and in solid state. 
SEEBACH’S group has focused on the β-peptides composed of conformationally 
flexible acyclic β-amino acids.[57, 63] Whereas, GELLMAN and coworkers have 
focused on conformationally constrained cyclic residues with limited degree of 




2. Bases and design of the β-peptide 
Several helical secondary structures are known for β-peptides including the 14-
helix, 12-helix, 10/12-helix, and 10-helix. The nomenclature of the β-peptide 
helices is based on the pattern of hydrogen bonding and the number of atoms in 





Figure 2.1.  A) The main chain torsional angles of a β-peptide and an α-peptide; B) nomenclature for β-peptide 




Although helical conformations are most common structural motifs for α-peptides, 
they are significantly different from β-peptide helices. A comparison of a α-helix 
with the β-peptide helices is represented in Figure 2.2.  
All three helical structures differ from each other significantly by polarities with 
respect to their C- and N-termini, radius, and number of residues per turn. The 14-
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helical structure is stabilized by hydrogen bonding between an amide proton (N-H) 
at position i and a main chain carbonyl group (C=O) at position i+2, forming a 




Figure 2.2.  Schematic representation of three helices: regular α-helix (left), 31-helix (14-helix) (middle) and β-
peptide 2.51-helix (12-helix) (right). This figure shows the polarities, pitches and diameters of the helices and 




The overall structure of the 14-helix differs from that of the α-helix in many aspects 
like radius, polarity, and overall dipole. The net dipole of the 14-helix is opposite to 
that of a α-helix as the amide carbonyl and NH groups project towards the N- and 
C-terminus, respectively. Furthermore, a β-peptide 14-helix has approximately 
three residues per turn, which positions the side chains of every third residue on 
the same side of the helix with linear orientation. GELLMAN and coworkers have 
shown that a short β-peptide composed of trans-2-aminocyclohexanecarboxylic 
acid (ACHC) adopts a 14-helical conformation in solid state and in solution.[64, 65] 
β-Peptides are able to adopt various stable secondary structures (helix, turn, and 
sheet) which indicates that it should be possible to design functional mimics of 
natural peptides and proteins. Several β-peptides were shown to exhibit interesting 
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biological activities.[59] β-Peptides are extremely stable towards all common 
proteolytic enzymes in vivo and in vitro.[66-67] It has been recently shown that β-
amino acids offer useful structural diversity in designing peptidomimetics.[62] 
Amphiphilic β-peptides are shown to mimic the amphiphilic α-helices involved in 
lipid uptake and transport in human apolipoproteins.[68] They are also known to 
function as potential antimicrobial agents. Antimicrobial agents can kill bacteria by 
interacting and disrupting the integrity of the cellular membranes. So far 
antimicrobial β-peptides have been prepared with either 14-helical or 12-helical 
conformations. Several amphiphilic oligomers with 14-helical conformation have 
been studied to function as antimicrobial agents.[69] Cyclic β-peptides and mixed α- 
and β-peptides are known to self-assemble in tubular architectures, which can be 
used as ion-conducting channels in phospholipid bilayers.[70-71] Therefore, it is clear 
that β-peptides which adopt several novel secondary structures, should be used to 
understand the fundamental implications of molecular assembly as well as in the 
field of designing pharmaceuticals and molecular devices. 
 
2.2. Nucleobase-functionalized β-peptides (β-PNA) 
 
The most prominent helical secondary structure in β-peptides is the 14-helix with 
three amino acids per turn orienting every third side chain (i and i + 3) on the same 
side of the helix.[65,69, 72-77] This helix is obtained with β-amino acids that have 
lateral substituents in β-position. Nevertheless, the helix propensity can be even 
improved by incorporation of conformationally constrained cyclic amino acids like 
trans-(1R,2R)-2 aminocyclohexanecarboxylic acid (ACHC).[65, 69, 72-75] The 
combination of stable helix formation and the uniform orientation of every third 
amino acid side chain offers the unique opportunity to use β-peptides for molecular 
architecture with peptide helical secondary structures (Figure 2.3). One possibility 
for using β-peptide helices for molecular architecture, the self-association of 
amphiphilic β-peptide 14-helices driven by hydrophobic interactions has already 
been reported.[78] In addition, specific helix interactions might be obtained by using 
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the recognition potential of hydrogen bonding. The nucleobase pair recognition 
known from oligonucleotides seems especially well suited for specificity and stable 
dimerization, since stacking interactions contribute to the overall stability. As 
already reported for α-peptides, the modification of amino acid side chains with 
nucleobases can be used for specific and reversible helix recognition and three-
dimensional organization.[79-81] Furthermore, nucleobase-functionalized α-helices 
can recognize DNA [82-83] or a complementary α-helix.[84-86] Base pairing provides 
an excellent driving force and selectivity for self-assembling β-peptide 14-helices. 
The principle design and first evidence for specific recognition of nucleobase-










2. Bases and design of the β-peptide 
The synthesis and recognition of a variety of β-peptide helices in order to 
investigate the stability of double-strand formation by comparison of the A–T and 
G–C pairing contributions has been reported.[88] Furthermore, geometrical 
parameters like the preferred strand orientation, the positioning of β-homolysine 
within the β-peptide helix, and the influence of the helix content on duplex 
formation have been evaluated. The functionalization of one helical face with three 
nucleobases already leads to very stable complexes in case of G–C recognition,[87] 
whereas A–T pairing β-peptides with the same oligomer length are significantly 
less stable. β-Peptide helices with four nucleobases in order to obtain defined 
double strands based on the four canonical pairing possibilities A–T, T–A, G–C, 
and C–G have been investigated.[88] The peptides, which contain 13 amino acids, 
were presented with the nucleo-β3-amino acids (S)-γ-(guanine-9-yl)-β-homoalanine 
(H-β-HalG-OH), (S)-γ-(cytosine-1-yl)-β-homoalanine (H-β-HalC-OH), (S)-γ-
(adenine-9-yl)-β-homo-alanine (H-β-HalA-OH) and (S)-γ-(thymine-1-yl)-β-
homoalanine (H-β-HalT-OH) incorporated in every third position as a recognition 
unit. For the remaining two positions per turn, β-homolysine was incorporated to 
increase the solubility in aqueous media and ACHC was introduced to achieve 
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Figure.2.4. A) Triplet sequences of the β-peptide with ACHC, nucleobase and β-homolysein; B) The used 
nucleobase- β
3
-amino acids in the previous right-handed 14-helix sequence. 
 
The strand orientation has been investigated with several nucleo-β3-amino acid 
sequences of the β-peptide 14-helix (β-PNA).[88] The sequence TAGT (5) and 
ACTA (6) or ATCA (7) and TGAT (8) are two pairs of oligomers that are 
complementary with antiparallel-strand orientation. In contrast, oligomers TAGT (5) 
and ATCA (7) or ACTA (6) and TGAT (8) are two complementary pairs designed to 
form a heterodimer, if parallel-strand orientation is preferred (Figure 2.5). All 
thermal denaturation studies with UV and CD spectroscopy have been proven to 
be reversible. There is a clear preference of β-PNA helices to undergo base-pair-
mediated organization with stable antiparallel helix orientation.  Such unexpected 
stability for only four base pairs most likely arises from the preorganization of the β-
PNA helices. Other reason could be the additive effect of WATSON-CRICK and 





2. Bases and design of the β-peptide 
 
 
Figure 2.5. β-PNA sequences designed to prove a preference for antiparallel or parallel helix orientation.
[88] 
 
The oligomers (5) TAGT and (6) ATCA are very interesting due to their thermal 
stability (Tm= 43 °C) in antiparallel double strands and none self-pairing. Therefore, 
those sequences have been chosen to be used as recognition units for the SNARE 
protein. The oligomers ATCA and TAGT are bounded to the native linker and 
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3. Design and synthesis of new artificial model 
systems for SNARE proteins 
 
3.1 Design of model systems 
 
Membrane fusion, one of the most fundamental processes in life, occurs when two 
separate lipid membranes merge into a single continuous bilayer.[4] This process is 
triggered by the specific action of fusion proteins like neuronal SNARE proteins in 
the case of synaptic transmission.[19] In order to promote exocytotic fusion of 
synaptic vesicles in presynaptic nerve endings, a coiled-coil four-helix bundle 
between two SNARE proteins residing in the plasma membrane (syntaxin-1A and 
SNAP-25) and a SNARE protein residing in the membrane of synaptic vesicles 
(synaptobrevin 2 or VAMP2) is formed, forcing the two merging membranes in 
close proximity (Figure 3.1).[19] However, the precise mechanism by which SNARE 
proteins execute the merger of the lipid bilayers is still unclear.[89]  
 
 







3. Design and synthesis of new artificial model systems for SNARE 
proteins 
There are two ways to study membrane fusion processes: 1) investigation of the 
native fusogenic proteins,[33, 40] or 2) designing various artificial model systems with 
reduced complexity.[90, 91] Artificial model systems simplify the complex natural 
systems and allow the systematical variation of the chemical structure and 
composition of these systems, in order to study the influence of each segment on 
the fusion process.  Accordingly, design and synthesis of novel model systems for 
synaptic SNARE proteins is the major goal of this study. The tansmembrane 
domain showed to have an important role in the fusion process. Therefore, it was 
decided to use membrane anchors based on native transmembrane domains and 
linker regions of syntaxin-1A (Sx) or synaptobrevin 2 (Sb) in our new model 




Figure 3.2. Schematic structure of syntaxin-1A (SNARE motif–red; linker region–grey; TMD–orange) and 
synaptobrevin 2 (SNARE motif–blue; linker region–light violet; TMD–violet).
[97] 
 
The SNARE recognition motif was replaced by β-PNA oligomers TAGT and ACTA 
(Figure 3.3), which are known to form a stable antiparallel duplex.[88]  β-PNA offers 
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a conformational rigid linear topology as a stable 14-helix and can be obtained with 
six β-amino acids (two helix turns). They have a high thermal stability and 
resistance towards enzymatic degradation. Therefore, β-PNA was implemented in 
the SNARE analogs with distance regulating properties for studying the vesicle 
membrane docking and fusion.  
 
 
Figure 3.3. SNARE protein mediated membrane fusion (left) in comparison to fusion mediated by a 
TMD/linker/-PNA construct (right). 
Initially, the β-PNA-peptide model system (ACTA-Syx and TAGT-Sb) with the 
transmembrane and linker domains of the natural SNARE and β-PNA sequences 
as recognition units was designed (Figure 3.4, up). β-PNA consists of two strands, 
each of them has four helix turns (about 20 Å), which play the role as distance 
regulator between the opposite membranes.  Later, the model system has been 
modified to investigate the influence of elongated β-PNA recognition units on the 
vesicle fusion. Thus, the constructs ACTA-ext-Syx and TAGT-ext-Sb were 
designed so that the hybrids contain an extended β-peptide 14-helix within the 
linker region (Figure 3.4, down). The last N-terminal six -amino acids before the 
-PNA starts were exchanged for -amino acids. Therefore, a continuous rigid 14-
helix can be formed extending the -PNA strand into the linker region. This 
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extension was provided on both sides of the -PNA recognition motif, thereby, 
extending the linear 14-helix -peptide from 20 to 40 Å. The sequences for the six 
-amino acid extensions were adapted from the linker sequences of syntaxin and 
synaptobrevin including ACHC units to ensure the -peptide 14-helix propensity 




Figure 3.4. up) Nucleobase functionalized β-peptide SNARE derived fusion system containing the native 
transmembrane domains (TMD) and linker sequences of synaptobrevin (Sb, blue) and syntaxin-1A (Syx, red) 
connected to β-peptide nucleic acid recognition units (green). Down) β-PNA SNARE analogs with extended -
peptide 14-helices in the linker region (green). TMDs and most of the linker sequences are derived from 
synaptobrevin (Sb, blue) and syntaxin-1A (Syx, red). 
 
Thus, two artificial model systems for SNARE proteins with different length of the 
14-helix β-peptide are designed and investigated in this work. Those β-PNA 
SNARE model systems can deliver further insight into the antiparallel fusion 




3. Design and synthesis of new artificial model systems for SNARE 
proteins 
3.2 Synthesis of β-PNA-peptides 
3.2.1. Manual solid phase peptide synthesis 
 
Peptide synthesis is largely based on the solid phase method developed in 1963 
by R. B. MERRIFIELD.[92, 93] The C-terminal amino acid of the peptide is linked via a 
cleavable linker to an insoluble polymer support (resin). The side-chain functional 
groups and N-α-amino group of the amino acids are protected with orthogonal 
protecting groups. The N-α-amino protecting group (9-fluorenylmethoxycarbonyl 
(Fmoc), tert-butyloxycarbonyl (Boc)), is then cleaved and the growing peptide chain 
is extended stepwise towards the N-terminus by repeating the 
coupling/capping/deprotection cycles, until the protected target peptide has been 
assembled (Figure 3.5). All soluble reagents can be removed from the peptide-
solid support by filtration and washed out at the end of each coupling step. 
Cleavage of the peptide from resin, and concurrent removal of all side-chain 
protecting groups is usually conducted by acidolysis. Depending on the nature of 
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Change of protection group strategy, solid support and development of more 
efficient coupling reagents leads to higher yields and suppression of side 
reactions.[99] However, particular difficulties arise due to intermolecular aggregation, 
steric hindrance of protecting groups and premature termination of the sequence.  
 
Peptide bond formation is a condensation reaction between two amino acids when 
the amino group of one amino acid reacts with the carboxylic group of the other 
amino acid, releasing a molecule of water. The carboxylic acid should be activated 
by making its hydroxyl group, a better leaving group. Quite a number of 
compounds activating carboxylic acids (coupling reagents) have been employed in 
peptide synthesis. In a recent review, a variety of such coupling reagents for amide 
bond formation has been comprehensively discussed.[94] The most-widely used 
coupling reagents are carbodiimides on one hand, and phosphonium and aminium 





Figure 3.6. Coupling reagents. 
 
Dicyclohexylcarbodiimide (DCC) is a classic member of carbodiimides family of 
coupling reagents, which has been used as carboxylic acids activator since 
1955.[95] But it has some limitations in use, e.g. these reagents cause dehydration 
of Asn and Gln residues. The other group of coupling reagents is the 









Figure 3.7.  HATU, HBTU, HOBt and HOAt coupling reagents. 
 
Coupling reagents derived from HOAt or HOBt react with a carboxylic acid to form 
reactive acyluronium (in case of HATU/HBTU) species which are then immediately 
transformed into R(CO)OAt or R(CO)OBt esters in the presence of HOAt or HOBt, 
respectively. A tertiary amine (e.g. DIEA) is usually added in order to deprotonate 





Figure 3.8. Mechanism of amide bond formation using HATU (R1, R2 are side chains and B is a Base). 
 
A direct attack of an amino group on the uronium/aminium coupling reagent to form 
guanidinium salt as a by-product is a very important side-reaction. Coupling 
reagents based on HOAt have several important advantages over the HOBt-based 
compounds. They have been shown to dramatically shorten the reaction time and 
to give target products in higher yields with less racemization.[96] 
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There are two strategies for peptide synthesis Fmoc and Boc strategies and the 
most commonly used one is Fmoc strategy. In addition, the Fmoc method is easy 
to use and Fmoc group can be cleaved under mild basic condition, in contrast, the 
Boc method requires strong acidic conditions for the cleavage (usually neat 
trifluoroacetic acid TFA). The removal of side-chain protecting groups and the 
cleavage of the peptide from the resin at the final stage of the synthesis are 
achieved by incubating in hydrofluoric acid or trifluoromethanesulfonic acid, which 
makes the Boc chemistry generally disfavored. Nevertheless, Boc strategy is 
suited to synthesize difficult, hydrophobic and unnatural peptide chains and reduce 
peptide aggregation. Therefore, the synthesis of β-PNA-peptide oligomers has 
been carried out by using Boc-SPPS. 
The general scheme which outlines the strategy of peptide synthesis was shown in 
Figure.3.5. Initially, the first Boc amino acid is attached covalently to an insoluble 
support resin on a HF or TFMSA cleavable linker. Deprotection of Boc, is 
accomplished by treatment of the peptide with TFA (Figure 3.9). The second Boc 
amino acid is coupled utilizing a pre-activated species or in situ activation. After the 
synthesis of the desired peptide, the resin bound peptide is deprotected and 




Figure 3.9. Mechanism of Boc deprotection. 
 
3.2.2. Manual SPPS of TMDs of syntaxin-1A and 
synaptobrevin 2 
 
The synthesis of TMD/linker sequences of syntaxin-1a (Syx-linker-TMD) and 
synaptobrevin 2 (Sb-linker-TMD) is difficult due to the high content of hydrophobic 
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amino acids (Figure 3.10). Hence, to increase the yield and make the method 
efficient for continuous coupling of the β-amino acids, in situ neutralization SPPS 
for assembly of Syx-linker-TMD and Sb-linker-TMD was used starting from PAM 
resin.[100] The standard reagents and procedures (see section 7.6.3) were 




Figure 3.10. TMD and linker sequences of syntaxin-1A (Syx-linker-TMD) and synaptobrevin 2 (Syb-linker-
TMD).a) TMD and Linker domains of (ACTA-Syx and TAGT-Sb); b) TMD and Linker domains of ACTA-ext-Syx 
and TAGT-ext-Sb. 
 
The synthesized Syx-linker-TMD and Sb-linker-TMD were soluble in 2,2,2-
trifluoroethanol (TFE). Unfortunately, the strong hydrophobic sequences and the 
poor solubility in water, methanol and acetonitrile were making the purification of 
these peptides by reversed phase HPLC impossible. However, the proof of 
successful formation of Syx-linker-TMD and Sb-linker-TMD could be only achieved 
by LC-MS. This proof allowed us to continue the synthesis of β-PNA-peptide 
hybrids directly, without cleavage from the solid support and further purification of 
the TMD part. 
3.2.3. Synthesis of β-amino acids 
 
Due to the increased number of possible configurational isomers of β-amino acids, 
a number of synthetic strategies are available. The preparation of enantiopure β-
amino acids has been extensively reviewed by many authors and several synthetic 
strategies have been already developed.[101-104] The most classical and 
conventional pathway is the ARNDT-EISTERT homologation of α-amino acids.[105] 
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The N-protected amino acids can be converted to the corresponding diazoketones 
via reaction of the mixed anhydride derivatives with diazomethane which undergo 




Figure 3.11. Reaction route to synthesis β-amino acids 
 
The β-amino acids Boc-β-HLys(Z)-OH, Boc-β-HTyr(2-Br-Z)-OH, Boc-β-HTrp(For)-
OH, Boc-β-HAla-OH, Boc-β-HSer(Bzl)-OH and Boc-β-HGln-OH, were synthesized 
by using the above mentioned strategy starting from the corresponding α-D-amino 
acid.[106]  
 
3.2.4. Synthesis of nucleo-β-amino acids 
 
In the previous section it was shown, that several methods are available for the 
synthesis of enantiomerically pure β-amino acids. Several methods known for the 
preparation of β-amino acids with proteinogenic side chains are not applicable to 
the synthesis of nucleo- β-amino acids. The ARNDT-EISTERT homologation of 
aromatic α-amino acids as a standard procedure is expected to proceed with 
partial racemization.[105] Therefore, this pathway is not suitable for the preparation 
of enantiomerically pure nucleo-β-amino acids.  
β-Homoserine derivatives are used as a starting material to access the synthesis 
of nucleo-β-amino acids. Reduction of the commercially available Boc-L-
Asp(OBzl)-OH leads to the required β-homoserin derivative which reacts with N3-
benzoyl pyrimidine (thymine) to give the desired nucleo-β-amino acid.  The 
MITSUNOBU reaction is the key step in the synthesis of pyrimidinyl-nucleo-β-amino 
acid (S)-N-Boc-β-HalT-OH (Figure 3.12).[107] The (S)-N-Boc-β-HalC-OH is 
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synthesized from the corresponding mesylate of the β-homoserine derivative by 




Figure.3.12. Synthesis of Boc-β-HalT-OH and Boc-β-HalC-OH starting from β-homoserin derivative. 
 
In case of the purine nucleobases (A and G), the β-homoserine derivative strategy 
gives very low yields. Since β-amino acids are well-known precursors of β-lactams, 
the reverse route (β-lactam → β-amino acid) is one of the simplest pathways used 
for the synthesis of enantiomerically pure β-amino acids and is more suitable for 
purine nucleobases adenine and guanine.[108] The β-lactam mesylate is obtained 
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from the L-aspartic acid  in four steps according to the procedure of SALZMANN et 
al.[107] Reaction of β-lactam mesylate with 2-amino-6-chloropurine under basic 
conditions furnishes guaninyl-β-lactam.[107] After selective hydrolysis of the β-
lactam ring, followed by Boc- protection, the guaninyl-β3-amino acid is obtained. 
Similarly, adenine is selectively alkylated with β-lactam mesylate providing 
exclusively adeninyl-β-lactam. The desired adeninyl-β3-amino acid is obtained after 





Figure 3.13. Synthesis of Boc-β-HalG-OH 
[109]
 and Boc-β-HalA-OH 
[110]
  starting from the mesylated β-lactam. 
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The nucleo-β-amino acids (S)-N-Boc-β-HalA-OH and (S)-N-Boc-β-HalG-OH have 
been synthesized starting from β-lactam as it is shown in Figure 3.13.[109, 110] 
 
3.2.5. Continuous SPPS of PNA/TMD hybrids 
 
The transmembrane domain and linker regions of native syntaxin-1A and 
synaptobrevin 2 were synthesized by manual Boc-SPPS. The peptides (Syx-TMD 
and Sb-TMD) and shortened linker analogs were synthesized in the same way on 
the PAM resin. The following assembly of β-PNA recognition units (ACTA for 
syntaxins and TAGT for synaptobrevins) was performed manually on 25 µmol 
scale as described in section 7.6.4. Finally, the synthesized hybrids were cleaved 
from a solid support under very strong acidic conditions with simultaneous 
deprotection of all side chain protecting groups. Unfortunately, the purification was 
impracticable due to very poor solubility of the oligomers. Thus, the hybrids (ACTA-
Syx, TAGT-Sb, ACTA-ext-Syx and TAGT-ext-Sb) were applied without further 
purification in previously designed model systems for synaptic SNARE proteins 




Figure 3.14. The synthesized and employed β-PNA/peptide hybrids in this work. 
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4. β-PNA/peptide hybrids in membranes 
 
4.1. Insertion of β-PNA/TMD hybrids in membranes 
 
The analysis of β-PNA/peptide hybrids distribution in vesicle membranes was 
performed in unilamellar vesicle systems consisting of DOPC/DOPE/cholesterol 
lipids (50/25/25). These large unilamellar vesicles (LUVs) with a diameter of 
100 nm were obtained using an extrusion technique following literature 
protocols.[111] The peptide/lipid complexes were formed at an early stage of vesicle 
preparation by mixing stock solutions of the highly hydrophobic β-PNA/peptide 
constructs in TFE and the lipid species in chloroform. The following evaporation of 
solvents and treatment of the residue with aqueous buffer solution (20 mM HEPES, 
100 mM KCl, 1 mM EDTA, 1 mM DTT pH = 7.4) led to the formation of 
multilamellar vesicles and final extrusion through a polycarbonate membrane (pore 
diameter 50 or 100 nm) providing unilamellar vesicles of corresponding size. 
HEPES buffer is widely used in physiological studies and maintaining the 
physiological pH while DTT can reduce the disulfide bond.  
 
4.2. Distribution of the fluorophores in lipid membranes 
 
Fluorescent lipid derivatives containing 7-nitrobenz-2-oxo-l, 3-diazol (NBD) have a 
bright yellowish-green fluorescence and high quantum yields. The electron-
withdrawing nitro group at position 7 of NBD participates in delocalization of 
electrons in the conjugated ring system (Figure 4.1). The reduction of the nitro 
group to an electron-donating amino group changes the electronic transitions of 
this molecule and its fluorescence dramatically.[112] In aqueous solutions, a 
dithionite ion (S2O4
2-) is in an equilibrium with a SO2
- radical anion. This radical, by 








Figure 4.1. Reduction of NBD with sodium dithionite.  
 
For measuring membrane lipid asymmetry, a simple fluorescence assay based on 
the reduction of NBD-fluorophores with sodium dithionite is employed.[112] This 
assay has been used to distinguish between hemifusion (merging of the outer 
leaflets of membranes only) and full fusion (merging of both outer and inner 
leaflets) of vesicles. Both charged dithionite ions (S2O4
 2-) and the corresponding 
radical anions (SO2
-) are unable to penetrate the hydrophobic vesicle membranes, 
and therefore, the NBD-fluorescence from the outer leaflet can be eliminated by 
treatment with sodium dithionite selectively. Sodium dithionite has previously been 
used to reduce nitrotyrosine residues to the corresponding aminotyrosins without 
affecting the overall protein structure.[115,116] Therefore, this reagent was employed 
for reduction in fluorescence studies with synthesized β-PNA/peptide conjugates. 
In order to estimate the distribution of the labled DOPE lipid with NBD-fluorophore 
between outer and inner leaflets of the vesicles, the vesicle was treated with 
sodium dithionite. The decrease of the NBD-emission up to 40 % from the starting 
value was observed (Figure 4.2). That means that about 60 % of NBD-DOPE was 
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Figure 4.2. Fluorescence change after treatment of NBD labeled lipid vesicles containing with sodium 
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5. Fusion activity of PNA/TMD model systems 
 
5.1. Vesicle fusion conditions 
 
The membrane fusion mediated by native fusogenic proteins as well as by 
synthetic model analogues has predominantly been studied in liposomes. 
Liposomes are subdivided into small unilamellar vesicles (SUVs, diameter 
< 100 nm), large unilamellar vesicles (LUVs, diameter 100-1000 nm) and giant 
unilamellar vesicles (GUVs, diameter > 1000 nm). The lipid composition, size, 
surface charge and peptide/lipid ratio of such liposomes can be easily controlled. In 
this study, LUVs with an average diameter of 100 nm were employed for 
investigating fusion activity of synthesized PNA/TMD hybrids. 
The LUVs with a lipid composition of DOPC/DOPE/cholesterol (50/25/25) were 
prepared by extrusion through a polycarbonate membrane with a nominal pore size 
of 100 nm. The radius distribution of the prepared vesicles containing TAGT-Sb 
and ACTA-Syx was determined by dynamic light scattering (DLS) and the average 
diameter was found to be 140 nm (Figure 5.1). The average diameter of prepared 
vesicles was determined for each population and was always in the same range. 

































Figure 5.1. DLS Measurements of the vesicles radius after extrusion; vesicle size with TAGT-Sb (left) and 
vesicles with ACTA-Syx (right). 
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Two populations of vesicles, the labeled ones (doped with 1.5 % of NBD-DOPE as 
a donor dye and 1.5 % of Rh-DOPE as an acceptor dye, with an overall 
concentration of DOPE 25 %), and the unlabeled ones were prepared for the lipid 
mixing assay experiments. First TAGT-Sb and ACTA-Syx were incorporated in 
these labeled and unlabeled vesicles, respectively. It has been found, that the 
peptide to lipid ratio (P/L)   1:200 shows maximal increase in the NBD 
fluorescence.[97]   By mixing both vesicle populations in different proportions, the 
highest increase in the donor fluorescence has been also found to occurs at a 1 to 
4 ratio of labeled to unlabeled vesicles, respectively.[97] Therefore, this ratio was 
employed for all following lipid mixing and content mixing experiments. 
Thus, all following fusion experiments for the seven different model systems were 
carried out in 100 nm LUVs with a lipid composition of DOPE/DOPC/cholesterol of 
50/25/25 and a peptide/lipid ratio of 1/200. 
 
5.2. Membrane fusion study assays 
 
5.2.1 Lipid mixing assay 
 
The lipid mixing assay is the most frequently used technique to monitor membrane 
fusion.[117] This method is based on the physical phenomenon of fluorescence 
resonance energy transfer (FRET). When the fluorescence donor (e.g NBD) and 
acceptor (e.g. lissamine rhodamine (Rh)) are located in one population of vesicles, 
the distance between both dyes is appropriate for an efficient FRET (Figure 5.2, A). 
If the membranes of fluorophore-labelled and non-labelled vesicles merge together, 
the average distance between donor and acceptor dyes increases, leading to a 
decrease of FRET efficiency and increase of donor emission (Figure 5.2, C). 









Figure 5.2. Sketch of the fusion techniques. A. Lipid mixing assay; B. Inner leaflet lipid mixing assay. 
Fluorescent donor (NBD) and fluorescence acceptor (Rh) are depicted yellow and pink, respectively; C. 
Fluorescence spectra of vesicles containing donor (NBD) and acceptor (Rh) dyes before the lipid mixing (blue 
curve) and after it (red curve).
[50] 
 
As already mentioned, the NBD-fluorophores from the outer leaflet of the vesicles 
can be selectively reduced with sodium dithionite.[112] This feature can be exploited 
to assess mixing of the inner leaflets of the membranes. If the mixing of 
fluorophore-labeled vesicles pretreated with sodium dithionite and non-labeled 
vesicles results in an increase of NBD-emission, it can only occur due to mixing of 
the inner leaflets of the membranes (Figure 5.2, B). Thus, the inner leaflet lipid 
mixing assay allows to distinguish between hemifusion (merging of the outer leaflet 
of membrane only) and full fusion (merging of both outer and inner leaflet of 
membrane).  
Both lipid mixing assays were performed using unilamellar vesicle systems 
comprised of DOPC/DOPE/cholesterol (50/25/25) lipids. NBD-DOPE (1.5 mol %) 
and Rh-DOPE (1.5 mol %) were used as donor and acceptor fluorescence dyes, 
respectively. The peptide/lipid complexes were formed by mixing stock solutions of 
the highly hydrophobic PNA/TMD hybrids in TFE and those of the lipid species in 
chloroform prior to formation of large unilamellar vesicles (LUVs). These LUVs with 
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5.2.2 Content mixing assay 
 
The most frequently used content mixing assay is based on the formation of a 
fluorescent complex of Tb3+ with dipicolinic acid (DPA).[118,119] In this method, 
vesicle populations containing encapsulated Tb3+ or DPA are prepared separately. 
Upon fusion of vesicles of these two kinds, a Tb3+/DPA complex is formed that 
leads to an increase of the observed fluorescence emmission. 
Alternatively, self-quenching assays with fluorescein, calcein or sulforhodamine B 
(SRB) dyes can be applied to this method.[120-122] In this study, the advantage of 
using SRB as a fluorescent dye in self-quenching assays was used. Thus, the 
fluorescence of SRB disappears almost completely due to the self-quenching at 
concentration higher than 30 mM, while for calcein and fluorescein these threshold 
concentrations are significantly higher (80 mM and 100 mM, respectively). 
Furthermore, SRB induces a very low osmotic pressure to the membrane 
compared to calcein. Thus, osmotic pressures of 50 mM SRB and calcein in 
20 mM HEPES are 0.066 Osmol/kg and 0.239 Osmol/kg, respectively. Due to the 
low osmotic pressure, the unspecific leakage for SRB is also lower than for calcein. 
The self-quenching content mixing assay was carried out in 100 nm LUVs with a 
lipid composition of DOPC/DOPE/cholesterol (50/25/25). Two populations of 
vesicles, the one with encapsulated 20 mM of SRB (self-quenching ≈ 80 %) and 
another one containing no dye (Figure.5.3, A) were prepared separately. If the 
mixing of vesicle contents (the fusion process) takes place upon mixing of both 
vesicle populations, the dilution of SRB dye occurs that leads to the observed 














Figure 5.3. Sketch of fusion techniques. A. Self-quenching content mixing assay. Sulforhodamine B is 
depicted in green; B. Fluorescence spectrum of vesicles containing sulforhodamine B (SRB) dyes before 




5.3. Fusogenic activity of β-PNA-peptide model system 
 
 
The SNARE-mimicking systems include TMD/linker segments from natural SNARE 
proteins, synaptobrevin 2 (Sb) and syntaxin-1A (Syx), and β-peptide nucleic acid 
(β-PNA) recognition motifs (Figure 5.4).  Such synthesized SNARE complex 
analogs can be assembled in antiparallel manner (Figure 5.4, up). Two different β-









Figure 5.4. schematic (up) and structural (down) SNARE simplified fusion system with β-PNA.  
 
Fusion experiments were performed using vesicles with diameter of (100 ± 20 nm), 
as determined by dynamic light scattering (see section 5.1). Vesicles containing 
TGAT-VAMP2 were prepared with nitrobenzofuran (NBD) as a donor dye and 
lissamine rhodamine (Rh) as an acceptor dye; both dyes were attached to the 
head group of the (DOPE) lipid while the other vesicle population containing ACTA-
Syx was unlabelled. During the fusion the distance between the dyes increase 
which can be indicated by a lower fluorescence resonance energy transfer (FRET) 
efficiency and higher donor emission (see section 5.2.1). Indeed, upon mixing of 
vesicles containing ACTA-Syx with vesicles containing TAGT-Sb, an increase in 
the NBD emission was observed and no changes have been detected by mixing 
the vesicles containing the same peptide TAGT-Sb (Figure 5.5). 
 
43 
5. Fusion activity of PNA/TMD model systems 
















Figure 5.5. Total lipid mixing detected by NBD emission of ATCA-Syx and TGAT-Sb vesicles (red); total lipid 
mixing assay of TGAT-Sb and TGAT-Sb vesicles (blue). 
 
The fusion of lipid bilayer requires merging of the inner and outer lipid leaflets of 
the membrane; therefore it is necessary to investigate whether the inner leaflet 
also merges. The previous experiment has been repeated after treating the 
labelled vesicle with sodium dithionite, thereby the NBD fluorescence in the outer 
leaflet is eliminated. Since the sodium dithionite is not able to penetrate the 
membrane, the emission from the inner leaflet stays intact.[123] An 56 % overall 
decrease in the NBD emission is expected for 100 nm vesicles and indeed we 
could measure about 62 % decrease upon addition of sodium dithionite. By 
indicating the NBD emission, an efficient lipid mixing was also observed by the 
sodium dithionit pre-treated vesicles, which proves that not only the outer leaflets 
fuses (hemifusion) but also the inner leaflets (full fusion) (Figure 5.6). 
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Figure 5.6. A) Total lipid mixing detected by NBD emission of ATCA-Syx and TGAT-Sb vesicles (black); inner 
leaflet lipid mixing (with dithionite) of ATCA-Syx and TGAT-Sb vesicles (red); total lipid mixing assay of TGAT-
Sb and TGAT-Sb vesicles (blue). B) NBD intensity upon addition of sodium dithionite (1) and complete 
elimination of fluorescence after destruction of the vesicles with 0.1% TritonX-100 (2). 
 
In order to prove that this system induces full fusion, we performed content-mixing 
experiments (Section 5.2.2). Sulforhodamine B (SRB) has fluorescence self-
quenching at high concentrations (˃10 mM) and is used in content-mixing 
experiment. Two vesicle populations were prepared, one encapsulates the SRB 
and the other is not labelled. By a fusion process it is expected to see an increase 
in the fluorescence caused by dilution of SRB. The leakage experiment has been 
also performed as a control experiment by using only the labelled vesicles (with 
SRB) and indicating the fluorescence over the same time period. Here we were 
able to see an increase in the SRB fluorescence in comparison to the leakage 
 
45 
5. Fusion activity of PNA/TMD model systems 
experiment. This experiment proves that the system induces full fusion where the 
outer and inner leaflets merge (Figure 5.7).  













Figure 5.7. Content mixing assay by using sulforhodamine B encapsulated in vesicles containing TGAT-Sb 
mixed with unlabelled vesicles containing ACTA-Syx (blue); leakage obtained with only labelled vesicles 
without mixing with unlabelled one (red). 
Lipid-mixing experiments were conducted at various temperatures to investigate 
whether the formed duplex is also stable as recognition unit. At 35 °C the fusion 
efficiency is higher than at 25 °C where the duplex is mostly paired and at 45 °C 
the efficiency has the same value as before, which is close to the melting 
temperature TM = 44 °C. Obviously, after reaching the melting point, the β-PNA still 
partly form a duplex. At 55 °C most of the duplex is unpaired and therefore the 
efficiency of the fusion is dramatically decreased (Figure 5.8). 
Thus, the lipid mixing experiments carried out with β-PNA/TMD SNARE analogs at 
various temperatures are in good agreement with the stability of the corresponding 
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β-PNA duplexes and therefore, can be predictably influenced by changing the 
temperature. 
 














Figure 5.8. Temperature-dependent lipid-mixing experiment of vesicles containing ACTA-Syx and TAGT-Sb at 
various temperatures. 
The last experiments have been shown clearly the fusogenic activity of the -PNA 
SNARE model system where the -PNA duplex in an antiparallel orientation was 
able to induce merging between the two different vesicles bilayers and mixing the 
aqueous content of the vesicles. Based on the hypothesis that the recognition motif 
with antiparallel strand orientation and opposed TMD linkers needs to be flexible or 
short to enable the interaction between vesicle membranes, we have investigated 
elongated -peptide helices. Therefore, TMD/linker/-PNA hybrids were 
synthesized that contain an extended -peptide 14 helix within the linker region. 
The last N-terminal six -amino acids before the -PNA starts were exchanged for 
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-amino acids. A continuous rigid 14-helix can be formed by extending the -PNA 
strand into the linker region. This extension was given on both sides of the -PNA 
recognition motif, thereby extending the linear 14-helix -peptide from 20 to 40 Å. 
The resulting TMD/linker/-PNA constructs containing extended 14-helices ACTA-
ext-Syx and TGAT-ext-Sb (Figure 5.9) were prepared in analogy to the other 
peptide -PNA hybrids. 
 
 
Figure 5.9. schematic (up) and structural (down) SNARE simplified fusion system with extended β-PNA 
peptides.  
Lipid-mixing experiments were carried out with the 14-helix extended -PNA 
peptides ACTA-ext-Syx and TGAT-ext-Sb. In comparison with fusion of ACTA-Syx 
and TAGT-Sb the extended -peptides showed less fluorescence increase and by 
that a significantly reduced fusogenicity (Figure 5.10, up). Studying the ACTA-ext-
Syx and TGAT-ext-Sb mediated vesicle fusion after treatment of the fluorophore 
labeled vesicles with dithionite, showed that lipid mixing was almost irrelevant and 
similar to the level of the control experiment mixing two TGAT-ext-Sb modified 
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vesicles. In order to prove that only hemifusion is induced by using the extended -
peptides, the content mixing assays were performed (Figure 5.10, down). The SRB 
Fluorescence increase was almost identical with the leakage experiment. This 
leads to the conclusion that lipid mixing mediated by the extended -PNA-peptides 
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Figure 5.10. Up) ATCA-ext-Syx and TGAT-ext-Sb fusion assay: total lipid mixing (black) and inner leaflet lipid 
mixing (with dithionite, blue). Total lipid mixing between TGAT-ext-Sb and TGAT-ext-Sb (red). Down) Content 
mixing assay with SRB encapsulated vesicles containing TGAT-ext-Sb and empty vesicles containing ACTA-
ext-Syx (blue), leakage obtained with only labelled vesicles without mixing with unlabelled one (red). 
 
50 
5. Fusion activity of PNA/TMD model systems 
This explication is supported by the content mixing assay. Fusing of an empty 
vesicle filled with a SRB, mediated by ACTA-ext-Syx and TGAT-ext-Sb, was not 
indicated since the fluorescence increase is in the range obtained by leakage 
(Figure 5.10, B). The different results obtained from vesicle membrane fusion 
mediated by -PNA recognition, leads to mechanistic conclusions. In spite of the 
rigid -PNA duplex structure and the restriction to pair with antiparallel stand 
orientation, membrane fusion is still efficient. The valuable aspect is the high 
duplex affinity for -PNA with only four base pairs which reaches the release of 
energy in the SNARE mediated fusion process. In addition, the antiparallel 
orientation of the recognition motif is not SNARE protein like and roughly is not 
favorable for fusogenicity. Notwithstanding, the short 20 Å -PNA recognition motif 
permits overcoming the unbeneficial orientation, brings the membranes in 
approximately close distance and promotes fusion (Figure 5.11). The TMD/linker/-
PNA constructs are likely to end up in the fused vesicle in a bridged form anchored 
twice by TMDs with the -PNA on the membrane surface. By prolongation of the -
PNA in the linker region the length of the rigid linear duplex structure will be longer 
and the distance of TMDs becomes large enough to hold the 100 nm vesicles 
away from each other, but still enables the interaction only with the outer leaflet 
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Figure 5.11. Lipid mixing of vesicle membranes mediated by antiparallel recognition: short recognition motif 
(20 Å) allows vesicle overlap resulting in fusion (upper line); extended recognition motif (40 Å) keeps vesicles 
on distance resulting in hemifusion (lower line). 
 
 
5.4. Parallel oriented β-PNA/peptide hybrid model 
system 
 
As it is known, two complementary nucleobase-functionalized β-peptides (β-PNAs) 
favor an antiparallel orientation over a parallel one, regardless of the nucleobases 
sequence (see section 2.2). But synthesizing such a parallel model enables an 
interesting comparison with native SNARE complex and the other artificial 
recognition units such as PNA and coiled-coil.  Therefore, we have designed a new 
model system and a possible strategy was developed to synthesize parallel β-PNA 









Figure 5.12. schematic (up) and structural (down) SNARE simplified fusion system with parallel β-PNA. 
 
The suggested strategy included synthesizing the TMD and linker domains of the 
synabtobrevin 2 using Boc-SPPS and coupling aspartic acid on the N-terminus 
then keeping the peptide on the resin with its protecting groups. The synthesis of 
the β-PNA recognition unit on MBHA resin should be performed using Boc-SPPS 
with Fmoc protecting groups on all amine groups and followed by the cleavage of 
the peptide from the resin, which has only one free amino group. A coupling 
reaction should be carried out between the free amino group of the cleaved peptide 
and the carboxyl group (COOH of Glu) of the peptide on the resin. In order to prove 
the validity of the mentioned method, two model peptides (Pep1 and Pep2) were 








Figure 5.13. Synthetic strategy of the simplified model system. 
 
 
The coupling reaction was successfully performed by using HATU, HOAt as 
activator and DIEA as activator base and the formation of the peptide (Pep3) was 
proven by mass spectroscopy. Therefore, this strategy can be applied to obtain the 
parallel recognition unit. The TMD-Sb and TAGT peptides were synthesized 
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Figure 5.14. Synthetic strategy of the parallel model system. 
 
The reaction could not be achieved and the product was not been detected. The 
sterical hindrance could play a major role through preventing the product formation. 
Probably, the free amino group does not have access to the carboxyl group on the 















Membrane fusion is a central process in biological systems. Despite intensive 
research in this field, many mechanistical questions remain unanswered. Therefore, 
model systems have been developed allowing in vitro investigation of the 
processes with reduced system complexity. Such systems allow simplification of 
the complex natural systems and systematic variation of the chemical structure and 
composition for understanding the fusion mechanism in detail. This extremely 
useful information would provide a chance to ultimately design artificial fusion 
systems with prescribed properties. Therefore, the fusogenic activity of new 
artificial model systems with varied structures and chemical properties is being 
constantly investigated. 
In this work, the novel simplified SNARE-mimicking systems consisting of 
TMD/linker segments of the natural membrane-bound SNARE proteins (syntaxin-
1A and synaptobrevin 2) with a nucleobase functionalized β-peptide (β-PNA) 
recognition motif were designed and synthesized (Figure 6.1 A). The β-PNA 
oligomers can form the 14-helix with three amino acids per turn orienting every 
third side chain (i and i + 3) on the same side of the helix. The β-PNA/TMD model 
system allows for creating artificial SNARE complexes which assemble 
preferentially in an antiparallel orientation (Figure 6.1 D).  
The synthesized β-PNA/TMD hybrids were shown to efficiently incorporate in 
vesicle membranes and after that, the corresponding recognition units remain 
available for interactions. The fusion experiments show that antiparallel orientation 
of the recognition motifs of the model systems turned out to be effective for fusion. 
The new PNA/peptide hybrids allow controlling fusion of vesicles depending on the 
temperature considering the duplex melting stability. The inner leaflet lipid mixing 
assay and content mixing assay experiments showed clearly, that the system 
induces full fusion where the outer and inner leaflets merge together. 
Derived from the previous model systems and the hypothesis that the antiparallel 




which contains an extended -peptide 14 helix within the linker region (Figure 6.1 
B). The fusion assay experiments indicated that the extended -PNA-peptides 
provide hemifusion involving only the outer leaflet with reduced efficiency.  
In this study the model system with a parallel -PNA recognition motif was 
designed (Figure 6.1 C). The synthesis of a simplified peptide model was 
presented to examine the ability of the coupling between two different peptide 
segments without any exchange of amino acids. Unfortunately, the application of 






Figure 6.1. A) Schematic SNARE simplified fusion system with β-PNA. B) Schematic SNARE simplified fusion 
system with extended β-PNA. C) Schematic SNARE simpli fied fusion system with parallel β-PNA. D) Fusion 
process mediated by a TMD/linker/-PNA construct (right). 
The short recognition motif (20 Å) permits bringing the vesicles in close spatial 
proximity and induces full fusion. While the extended recognition motif (40 Å) 
keeps vesicles on distance and leads to hemifusion. The -PNAs allow antiparallel 




native SNARE situation. Nevertheless, the artificial TMD/linker/-PNA constructs 
are surprisingly efficient in mediating membrane fusion. The -PNA recognition 
motif with the linear and conformational rigid 14-helix backbone offers an especially 
interesting option of distance control. 
In conclusion, this system offers a powerful tool to control the fusion state by using 
different length of -PNA. The extended -PNA leads to hemifusion state while the 
shortened one induces full fusion.  
Thus, the designed and synthesized β-PNA/TMD hybrids emerged as very 
attractive and promising artificial fusogenic systems, which is capable of inducing 
efficient fusion. Importantly, their structure elements such as membrane-anchored 
TMDs, linker regions and recognition units can be easily systematically modified on 
demand and the β-PNA recognition duplex formation is very selective and stable. 
Furthermore, the mechanism of an antiparallel model system could be shown as 













7. Materials and general methods 




All technical solvents were distilled prior to use. Anhydrous DMF, diethyl ether, 
TFE, THF, DCM and NMP were obtained from Aldrich, Fluka, Acros or Carl Roth 
GmbH, controlled by GS and used without additional purification. Piperidine was 
obtained from Riedel de Haen and used as supplied. Acetonitrile and methanol 
were of HPLC grade. Demineralized water (MiliQ) was processed from Simplicity 
system of Millipore (Bredford, UK). 
7.2. Reagents 
All chemicals were of the highest grade available and used as supplied. Boc-
protected amino acids were purchased from NovaBiochem, GL Biochem 
(Shanghai) Ltd., ACM Research Chemicals or PANAGENE Inc. (Daejeon):  
    Boc-Gly-OH 
    Boc-Phe-OH 
    Boc-Ile-OH 
    Boc-Ala-OH 
    Boc-Val-OH 
    Boc-Leu-OH 
    Boc-Asn-OH 
    Boc-Thr(Bzl)-OH 
    Boc-Ser(Bzl)-OH 
    Boc-Cys(pMeOBzl)-OH 
    Boc-Met(O)-OH 
    Boc-Arg(MTS)-OH 
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    Boc-Lys(2-Cl-Z)-OH 
    Boc-Trp(For)-OH 
    Boc-Tyr(2-Br-Z)-OH  
Resins for SPPS Boc-Gly-Pam-resin (loading 0.75 mmol/g) and Boc-Thr(Bzl)-Pam-
resin (loading 0.45 mmol/g) were purchased from Novabiochem (Merck). Boc-β-
amino acids and nucleobase functionalized β-amino acids (A, T, C and G) have 
been synthesized as described earlier.[87] Lipids and fluorophores were obtained 
from the Avanti Polar Lipids (Alabaster, USA). 
7.3. Lyophilization 
A Christ Alpha-2.4-lyophilizer equipped with a high vacuum pump was used to 
liberate dry substances from water. 
7.4. High performance liquid chromatography (HPLC) 
 
HPLC was performed on a Pharmacia Äkta basic system (pump type P-900, 
variable wavelength, detector of type UV-900) using the following columns: 
Analytical HPLC:  Phenomenex, synergi, Max-RP (150 x 4.6 mm, 5 µm) 
Phenomenex, RP C-18 (250 x 4.6 mm, 5 µm) 
 
All HPLC runs were performed by using a linear gradient of solvents A (0.1 % aq. 
TFA) and B (100 % Methanol, 0.1 % aq. TFA) within 30 min. For analysis and 
purification, HPLC grade acetonitrile and ultra pure water were used. Flow rates 
were taken as 1 mL/min for the analytical runs. All crude samples were dissolved in 
TFE-formic acid mixtures and filtered prior to injection. UV detection was 
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7.5. Further chromatographic methods 
 
Flash chromatography was performed using Merck silica gel 60. Thin layer 
chromatography (TLC) was carried out using Merck aluminum sheets of silica gel 
60 F 254 with detection under UV light at 254 nm or development with solution of 
ninhydrin in ethanol (2.0 g ninhydrin, 100 mL EtOH and 1 mL AcOH) followed by 
heating using a heat-gun. 
7.6. Solid phase peptide synthesis (SPPS) 
 
7.6.1. Handling of solid support and building blocks 
 
Amino acid building blocks were stored at -18 ºC. For the storage of resins for 
SPPS the temperature did not exceed 4 ºC. Before opening, chemicals were 
warmed to room temperature. If necessary, both resins and amino acids were 
additionally dried in high vacuum. 
7.6.2. Kaiser test 
 
The Kaiser test was used to confirm the successful coupling step by detecting the 
free amino groups on the resin. The solutions of ninhydrin in ethanol (5 g/100 mL), 
phenol in ethanol (80 g/20 mL) and aq. KCN (1 mM, 2 mL) in pyridine (98 mL) were 
prepared. A few beads of the resin were washed several times with ethanol and 
placed in a small glass tube. Two drops of each solution described above were 
added to the sample of resin. The resulting suspension was heated at 120 ºC for 
5 min. Blue color of resin beads indicated positive test result (presence of free 
amino groups on the resin), whereas a yellow color (negative test) confirmed the 
absence of the free amino groups and, therefore, completeness of the 
corresponding coupling step. It is worth to note, that the Kaiser test is not accurate 
 
61 
7. Materials and general methods 
(can provide false negative results) in the case of peptides containing proline, 
asparagine or serine residues. 
 
7.6.3. Manual SPPS for α-Peptides 
 
The SPPS of peptide conjugates was carried out manually at 25 µM scale using 
the Pam- resins.[100] The resins were suspended in the minimal amount of DMF 
and allowed to swell for 2 h. After the swelling was completed and the solvents 
were removed, the following procedure was repeated for each coupling cycle: 
1.  Boc-deprotection with TFA (≥ 99.9%), 2 times for 1 min each. 
2. Coupling: The corresponding building blocks (11 eq.) were dissolved in the 
minimal amount of DMF; HBTU (10 eq.) and DIEA (29 eq.) were added before he 
mixture was given to the resin gently shaking for 12 min. 
3. Capping: The unreacted amino groups were “capped” by shaking resins with the 
mixture of Ac2O (2 M), DIEA (0.6 M), HOBt (60 mM) in DMF, 2 times for 5 min 
each. 
4. Washing: After each step (deprotection, coupling, capping), the resin was 
washed with DMF and DCM at least three times using approximately 2 mL of 
solvent per 100 mg of resin. 
5. Final washing: Before final assembly of the synthesized constructs or before 
cleavage from solid support, the resin was washed with DMF (at least 3 times), 
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7.6.4. Manual SPPS for β-peptides  
 
After the synthesis of the TMD and Linker, the following β amino acids were 












After coupling of the last α-amino acids the coupling protocol for β-amino acids was 
applied.[88] The coupling cycle started with Boc-deprotection applying 95% TFA and 
5% m-cresol twice within 2 min, followed by washing with DMF (5 times). For each 
coupling, an excess of -amino acid building block of five equivalents was used; 
the -amino acids were dissolved in stock solutions of coupling reagents within 
5 min before the base was added. For activation of coupling HATU/HOAt 
(4.5 eq./5 eq.) in DMF were used. DIEA (14 eq.) was used as activator base. A 
0.25 M concentration was used as the final reaction mixture for the building blocks 
and HOAt. The HATU concentration was adjusted to 0.225 M. Standard coupling 
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time was 60 min at 50 °C. β-Amino acid building blocks were introduced by double 
coupling. The reaction time for the second coupling was kept as 60 min at 50 °C 
but the amino acids and activators concentrations were reduced (amino acid 3 eq./ 
HATU 2.5 eq./ HOAt 3 eq.).  After washing with DMF (5 times) and DCM (5 times) 
capping was fulfilled with Ac2O (2 M), DIEA (0.6 M) and HOBt (60 mM) in DMF 
within 30 min. Washing with DMF (10 times), DCM (10 times) completed the 




Peptides were cleaved from the solid support simultaneously removing the side 
chain protecting groups; standard TFMSA cleavage was applied using the mixture 
of thioanisole (15 μL), ethanedithiol (7.5 μL), m-cresol (15 μL), TFA (150 μL), and 
TFMSA (15 μL).[124, 125] In case the sequences contained a sensitive Trp residue 
the resin was pretreated with 10 % piperidine in DMF for 3 h; afterwards the 
previous mixture with additional DMS (15 µL) was applied. Cleavage reactions 
were carried out for 3 h at ambient temperature starting with 0°C for 5 min. 
7.6.6. Post-cleavage work up 
 
After cleavage, the resin was filtered and the resulting solution was concentrated 
under reduced pressure. The crude product was precipitated with cold Et2O. The 
resulting suspensions were centrifuged at 4 °C. The supernatant was discarded 
and the peptide pellet washed several times with Et2O and dried in vacuo. For 
mass spectrometry analyses peptide samples were dissolved in TFE/formic acid 
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7.6.7. Synthesis of /-peptide hybrid oligomers 
 
-/-Peptide hybrid oligomers were synthesized via manual SPPS on a Pam resin 
(loading: 0.75 mmol/g for syntaxin and 0.45 mmol/g for synaptobrevin) at a 
25 µmol scale. Peptides (ACTA-Syx, TGAT-Sb, ACTA-ext-Syx, TGAT-ext-Sb) were 
synthesized with manual SPPS for the α-peptide sequences Syx/linker and 
Sb/linker (see section 2.2) and continued with manual modified protocol for β-
peptides (ACTA, TGAT with or without 14-helix linker) (see section 2.3).  
 
7.7. Preparation of peptide/lipid complexes 
 
6.7.1. Multilamellar vesicles (MLVs) 
 
Lipids and cholesterol were dissolved in CHCl3 (about 20 mg·mL
-1), mixed with 
alcoholic peptide stock solutions (TFE) to form a solution of CHCl3 /alcohol (1/1, 
v/v) with defined P/L ratio. Removing the solvents in a nitrogen stream at 
temperatures above the main phase transition temperature of the respective lipids 
produced an almost clear lipid/peptide film at the test tube walls. After removing of 
residual solvent under reduced pressure for 12 h at T > tm, the lipid films were 
rehydrated with an appropriate amount of buffer solution (20 mM HEPES, 100 mM 
KCl, 1 mM EDTA, 1 mM DTT, pH 7.4) yielding the desired peptide concentration. 
After 1 h of incubation at T > Tm , the hydrated lipid films were vortexed (30 s) and 
incubated (5 min at 45 °C) in five cycles. The preparation of the unilamellar 
vesicles and other peptide/lipid complexes was carried out at temperatures above 
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7.7.2. Large unilamellar vesicles (LUVs) 
 
The milky MLV suspensions were extruded 31 times through a polycarbonate 
membrane (100 nm nominal pore size) using a Liposofast mini extruder (Avestin, 
Ottawa, Canada) to produce an almost clear vesicle suspension containing 
vesicles of 100 nm size with a low degree of polydispersity as determined by 
dynamic light scattering (see below).[126] 
7.8. Spectroscopic and analytical methods 
 
7.8.1. NMR Spectrometry 
 
 
1H- and spectra were recorded with a Varian Unity 300 spectrometer or a Varian 
Inova 600 spectrometer. Chemical shifts are referenced to the residual solvent 
peak of [D6] DMSO (1H: δ= 2.49 ppm) or CDCl3 (1 H: δ= 7.26 ppm). Chemical 
shifts are given in parts per million (ppm). Abbreviations for multiplicities are as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Coupling 
constants are given in Hz. 
 
 7.8.2. Mass spectrometry (MS) 
 
Electrospray ionization mass spectra (ESI-MS) were obtained with a Finnigan LCQ 
instrument. Liquid chromatography mass spectrometry (LC-MS) spectra were 
obtained with the Thermo (HPLC) and Finnigan (MS) instrument. A Phenomenex, 
MAX-RP Synergi C-18 (150 × 2 mm, 4 µm) column was used. All synthesized β-
PNA/peptide conjugates were characterized by ESI-MS and LC-MS. High 
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7.8.3. Dynamic light scattering (DLS) 
 
Experimental diffusion coefficients (D) were measured at 25 ºC by dynamic light 
scattering at a laser wavelength of 830 nm and scattering angle of 90º using a 
DynaPro Titan DLS. The Stokes-Einstein relationship: D = kBT/3pηDh (kB is the 
Boltzman constant and η the solvent viscosity) was used to estimate the 
hydrodynamic radius, Dh (nm). The radius of the vesicle containing ACTA-Syx was 
determined as 73 nm and with TAGT-Sb 75 nm.  
7.8.4. UV-Spectroscopy 
 
Peptide concentrations were estimated with a Jasco V5550 UV spectrometer 
(Gross Umstadt, Germany) while the sample cell was floated with nitrogen. 
Molecular absorption coefficients were calculated for each oligomer sequence via 
summation of the monomer absorption coefficients at a certain wavelength. 
Nucleobases and peptides conjugate concentrations were estimated at 260 nm. 
Concentrations were calculated with LAMBERT BEER’S law. 
ACTA-Syx and ACTA-ext-Syx: 
 
ε = 2(εAdenin) + εCytosin + εThymin 
ε = 2(15400) + 7400 + 8700 
ε = 46900 L·mol−1·cm−1 
 
TGAT-Sb and TGAT-ext-Sb: 
 
ε = 2(εThymin) + εGuanin + εAdenin + 2(εTryptophan) 
ε = 2(8700) + 11500 + 15400 + 2(5000) 
ε = 54300 L·mol−1·cm−1 
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7.8.5. Fluorescence spectroscopy 
 
Fluorescence spectra were obtained with a Jasco FP 5600 (Gross Umstadt, 
Germany) under temperature control using a thermostat (Model 1162A, VWR 
International, Darmstadt, Germany). The excitation and emission bandwidth was 
set to 5 nm, the data pitch was 1 nm and the response time was adjusted to 0.1 s. 
NBD-DOPE was used as fluorescence donor, rhodamine-DOPE as acceptor. Data 
were recorded at a P/L ratio of 1/200 in DOPC/DOPE/cholesterol (50/25/25) LUVs. 
 
7.8.5.1. Lipid mixing assay 
 
Lipid mixing assay excitation was performed at 460 nm with a detection of the 
fluorescence emission at 535 nm.[45, 117] NBD/rhodamine labeled vesicles (1.5 % 
NBD-DOPE and 1.5 % rhodamine-DOPE), containing TGAT-Sb peptide constructs 
(or TGAT-ext-Sb), were mixed with unlabeled vesicles, containing ACTA-Syx 
constructs (or ACTA-ext-Syx) at a defined ratio (1 to 4); the total lipid concentration 
in the cuvette was 180 µM. The reaction buffer was 20 mM HEPES, 100 mM KCl, 
1 mM EDTA, 1 mM DTT at pH 7.4 and the reaction temperature 25 ºC. The change 
in donor intensity is plotted as: 
 
F(%) = 100*(Ft .F0 )/(Ftotal .F0 ) 
 
with F0 being the donor intensity at t = 0 before lipid mixing and Ftotal the donor 
intensity after disruption of the vesicles in 1 % (w/v) Triton X-100. The same 
procedure was used for the inner leaflet mixing assay except NBD/rhodamine 
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7.8.5.2. Reduction of NBD/Rhodamine labeled vesicles 
 
A 1:1 mixture of NBD/rhodamine labeled vesicles (5 mM) and 50 mM Na2S2O4 
(20 mM HEPES, pH 7.4) was incubated at room temperature for 5 min. Free 
sodium dithionite was removed by gel filtration using Superdex G550 Superfine 
columns (GE Healthcare). Reduction was immediately carried out before use of the 
vesicles.[122] 
 
7.8.5.3. Content mixing assay 
 
A vesicle population with an encapsulated fluorophore (sulforhodamine B) is mixed 
with vesicles without sulforhodamine B. The observed increase of fluorescence 
caused by decreasing of fluorophore concentration indicates that vesicle contents 
are mixed and fusion takes place. Content mixing assay excitation was performed 
at 567 nm with a detection of the fluorescence emission at 583 nm. The vesicles 
containing TGAT-Sb (or TGAT-ext-Sb) constructs with encapsulated 
sulforhodamine B (20 mM in 20 mM HEPES, 100 mM KCl, 1 mM EDTA, 1 mM 
DTT, pH 7.4) were extruded through a polycarbonate membrane (100 nm nominal 
pore size). The free sulforhodamine B was removed by gel filtration using 
Superdex G550 Superfine columns (GE Healthcare). Unlabeled vesicles, 
containing ACTA-Syx constructs (or ACTA-ext-Syx), were prepared in the same 
way as described in section 3.2. Both types of vesicles were mixed at a defined 
ratio (1:4); the total lipid concentration in the cuvette was 180 µM. The reaction 
buffer was 20 mM HEPES, 100 mM KCl, 1 mM EDTA, 1 mM DTT, pH 7.4 and the 
reaction temperature was 25 ºC. The change in sulforhodamine B intensity is 
plotted as: 
 
F(%) = 100*(Ft .F0 )/(Ftotal .F0 ) 
 
69 
7. Materials and general methods 
 
with F0 being the sulforhodamine B intensity at t = 0 before content mixing and 
Ftotal the sulforhodamine B intensity after disruption of the vesicles in 1 % (w/v) 
Triton X-100. 
 
7.9. Synthesis of /-peptide hybrid oligomers 
 










Under dry conditions, Boc-D-Trp(For)-OH 1 (5.55 g, 10.7 mmol) was dissolved in 
dry THF  (50 mL) under exclusion of light. At ˗21°C triethylamine Et3N (1.63 mL, 
11.7 mmol) and isobutyl chlorformate (1.52 mL, 11.7 mmol) were added to the 
amino acid and stirred at ˗21°C for 45 min under argon. The mixture was warmed 
to 0°C and the diazomethane (30.46 mL, 21.3 mmol) was added over 30 min and 
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stirred at rt for 5 h. The reaction was stopped with acetic acid (1.4 mL) and EtOAc 
(75 mL) was added. The organic phase was washed with 6 % NaHCO3 (100 mL), 
NH4Cl (100 mL) and NaCl (100 mL). The extracted organic phase was dried over 
MgSO4 and the solvents were removed under reduced pressure. The resulting 
crude 2 was dissolved in THF: H2O (9:1) (75 mL) and the silverbenzoate (250 mg, 
1.1 mmol) was added at 0° C. After 2 h reaction time in ultrasonic bath the reaction 
mixture was neutralized with HCl (1 M) by reducing the pH to 2-3. The suspension 
was extracted with EtOAc (100 mL) and the organic layer was dried over MgSO4. 
The product crude was suspended in a pentane:DCM mixture (10:1) to crystallize 




ESI-MS: m/z = 347.1 [M+H+]+, 369.1 [M+Na+]+ , 385.1 [M+K+]+. 
 
ESI-HRMS: calculated for C18H22N2O5K 385.1160, found 385.1164 [M+K
+]+. 
 
1H NMR (300 MHz, CDCl3): δ=1.39 (s, 9H; Boc), 2.51-2.68 (m, 2H; α-CH2), 3.00 
(m, 2H; γ-CH2), 4.27 (d, J = 48.0 Hz, 1H; β-CH2), 7.21 (s, 1H; aromatic H), 7.3-
7.76 (m, 4H; aromatic H), 8.30-8.42 (m, 1H; NH), 9.04 (s, 1H; -CHO), 9.35 (s, 1H; -
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7.9.1.2. (S)-4-(4-((((2-bromobenzyl)oxy)carbonyl)oxy)phenyl)-3-((tert-




Under dry conditions, Boc-D-Tyr(2-Br-Z)-OH 4 (5.26 g, 10.7 mmol) was dissolved 
in dry THF  (50 mL) under exclusion of light. At ˗21°C triethylamine Et3N (1.63 mL, 
11.7 mmol) and isobutyl chlorformate (1.52 mL, 11.7 mmol) were added to the 
amino acid and stirred at ˗21 °C for 45 min under argon. The mixture was warmed 
to 0 °C and the diazomethane (30.46 mL, 21.3 mmol) was added over 30 min and 
stirred at rt for 5 h. The reaction was stopped with acetic acid (1.4 mL) and EtOAc 
(75 mL) was added. The organic phase was washed with 6 % NaHCO3 (100 mL), 
NH4Cl (100 mL) and NaCl (100 mL). The extracted organic phase was dried over 
MgSO4 and the solvents were removed under reduced pressure. The resulting 
crude 5 was dissolved in THF: H2O (9:1) (75 mL) and the silverbenzoate (250 mg, 
1.1 mmol) was added at 0° C. After 2 h reaction time in ultrasonic bath the reaction 
mixture was neutralized with HCl (1 M) by reducing the pH to 2-3. The suspension 
was extracted with EtOAc (100 mL) and the organic layer was dried over MgSO4. 
The product crude was suspended in a pentane:DCM mixture (10:1) to crystallize 
the pure product 6 (59 %) as a yellowish white solid. 
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ESI-MS: m/z 530.1 [M+Na+]+ , 546.1 [M+K+]+. 
 
ESI-HRMS: calculated for C23H26BrNO7Na 530.0785, found 530.0777 [M+Na
+]+. 
 
1H NMR (300 MHz, CDCl3): δ=1.37 (s, 9H; Boc), 2.46-2.68 (m, 2H; α-CH2), 2.81-
2.93 (m, 2H; γ-CH2), 4.15 (sbr, 1H; β-CH2), 5.09 (s, 1H, NH), 5.34 (s, 2H, -CH2 Z), 








Under dry conditions, Boc-D-Gln-OH 7 (3 g, 12.2 mmol) was dissolved in dry THF  
(50 mL) under exclusion of light. At ˗21°C triethylamine Et3N (1.71 mL, 13.4 mmol) 
and isobutyl chlorformate (1.74 mL, 13.4 mmol) were added to the amino acid and 
stirred at ˗21 °C for 45 min under argon. The mixture was warmed to 0 °C and the 
diazomethane (34.14 mL, 24.4 mmol) was added over 30 min and stirred at rt for 
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5  h. The reaction was stopped with acetic acid (1.5 mL) and EtOAc (75 mL) was 
added. The organic phase was washed with 6 % NaHCO3 (100 mL), NH4Cl 
(100 mL) and NaCl (100 mL). The extracted organic phase was dried over MgSO4 
and the solvents were removed under reduced pressure. The resulting crude 8 was 
dissolved in THF: H2O (9:1) (75 mL) and the silverbenzoate (285.43 mg, 1.2 mmol) 
was added at 0° C. After 2 h reaction time in ultrasonic bath the reaction mixture 
was neutralized with HCl (1 M) by reducing the pH to 2-3. The suspension was 
extracted with EtOAc (100 mL) and the organic layer was dried over MgSO4. The 
product crude was suspended in a pentane:DCM mixture (10:1) to crystallize the 




ESI-MS: m/z   260.2 [M+H+]+, 283.1 [M+Na+]+ , 299.1 [M+K+]+. 
 
ESI-HRMS: calculated for C11H20N2O5Na 283.1264, found 283.1259 [M+Na
+]+. 
 
1H NMR (300 MHz, [D6] DMSO): δ=1.37 (s, 9H; Boc), 1.61 (d, JH,H = 19.3 Hz; 2H; 
γ-CH2), 2.01-2.07 (td, JH,H = 7.2, JH,H = 3.8 Hz; 2H; δ-CH2), 2.29-2.34 (t, JH,H = 6.2 
Hz,  2H; α-CH2), 3.70 (d, JH,H = 5.4 Hz; 1H; β-CH2), 6.62 (d, 
3JH,H = 10.5 Hz 2H, 
NH2), 7.2 (s, 1H, NH), 12.06 (sbr, 1H; -COOH). ppm                  
 








7. Materials and general methods 
Pep1 was synthesized using the Boc-Gly-PAM-resin (20 µmol, 26.7 mg) according 
to the general procedure described in section 7.6.3. After the final coupling, 10 mg 
of the peptide resin was cleaved from the resin followed by lyophilization to afford 
the peptide as a white solid. 
 
ESI-HRMS: Calculated for C20H35N7O9Na  440.2393, found 440.2396 [M+Na]
+ 




C92H99N11O13 [1566.8 g/mol] 
 
Pep2 was synthesized using the Boc-β-Gly-MBHA-resin (25 µmol, 50 mg) 
according to the general procedure described in section 7.6.3. After the final 
coupling the peptide was cleaved from the resin followed by lyophilization to afford 
the peptide as a white solid. 
 
Analytical HPLC: (RP C-18, 250 x 4.6 mm, 5 µm): tR= 20.4 min, gradient: 5 to 70 % 
B in 30 min. 
ESI-HRMS: Calculated for C92H99N11O13  1588.7321, found 1588.7323 [M+Na]
+ 








7. Materials and general methods 
The coupling reaction between the peptides Pep1 on the resin and Pep2 was 
performed to obtain Pep3. The synthesis started with adding (HATU 1 eq, HOAt 
1 eq in DMF and 500 µl) and DIEA (7 µl, 6 eq) to 10 mg of the pep1 resin. Pep2 
(120 mg, in DMF, 500 µl) is added to the pep1 resin and shaked together at rt 
overnight. The peptide was cleaved from the resin followed by lyophilization to 
afford the peptide as a white solid. 
 
Analytical HPLC: (RP C-18, 250 x 4.6 mm, 5 µm): tR= 21.2 min, gradient: 5 to 70 % 
B in 30 min. 
ESI-HRMS: Calculated for C107H124N18O19  1987.9187, found 1987.9189 [M+Na]
+ 




C188H301N41O40S3 [3871.9 g/mol] 
 
TMD-Sb was synthesized using the Boc-Thr(Bzl)-Pam-resin (25 µmol, 28 mg) 
according to the general procedure described in section 7.6.3. After the final 
coupling, 10 mg of the peptide resin was cleaved from the resin followed by 
lyophilization to afford the peptide as a white solid. 
. 
 









C154H188N32O26 [2903.4 g/mol] 
 
TAGT was synthesized using the Boc-β-Gly-MBHA-resin (25 µmol, 50 mg) 
according to the general procedure described in section 7.6.4. After the final 
coupling the peptide was cleaved from the resin followed by lyophilization to afford 
the peptide as a white solid. 
 
Analytical HPLC: (synergi, Max-RP, 150 x 4.6 mm, 5 µm): tR= 25.6 min, gradient: 5 
to 70 % B in 30 min. 





C244 H413 N73 O52 S3 [ 5294.1 g/mol ] 
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ACTA-Syx was synthesized using the Boc-Gly-PAM-resin (20 µmol, 26.7 mg) 
according to the general procedure described in section 7.6.3 and 7.6.4. After the 
final coupling the peptide was cleaved from the resin followed by lyophilization to 
afford the peptide as a white yellowish solid. 
 
LC-MS: m/z = [M+3H]3+ calc: 1765.7, found: 1765.8; [M+4H]4+ calc: 1324.5, 






C279H443N71O55S3 [5764.32 g/mol] 
 
TGAT-Sb was synthesized using the Boc-Thr(Bzl)-PAM-resin (25 µmol, 28 mg) 
according to the general procedure described in section 7.6.3 and 7.6.4. After the 
final coupling the peptide was cleaved from the resin followed by lyophilization to 
afford the peptide as a white yellowish solid. 
 
LC-MS: m/z = [M+4H]4+ calc: 1442.1, found: 1442.2; [M+5H]5+, calc: 1153.9, 




7. Materials and general methods 
ACTA-ext-Syx 
 
C259H438N74O53S3 [5533 g/mol] 
 
ACTA-ext-Syx was synthesized using the Boc-Gly-PAM-resin (20 µmol, 26.7 mg) 
according to the general procedure described in section 7.6.3 and 7.6.4. After the 
final coupling the peptide was cleaved from the resin followed by lyophilization to 
afford the peptide as a white yellowish solid. 
 






C294H468N70O56S3 [5971.51 g/mol] 
 
TGAT-ext-Sb was synthesized using the Boc-Thr(Bzl)-PAM-resin (25 µmol, 28 mg) 
according to the general procedure described in section 7.6.3 and 7.6.4. After the 
final coupling the peptide was cleaved from the resin followed by lyophilization to 
afford the peptide as a white yellowish solid. 
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AA   amino acid 
Ac   acyl 
ACHC 2-aminicyclohexanecarboxylic acid 
aeg   aminoethylglycine 
ATP   adenosine-5'-triphosphate 
Boc   tert-butyloxycarbonyl 
calc.   calculated 
CD   circular dichroism 
CLSM  confocal laser scanning fluorescence microscope 
DAG   diacylglycerol 
DBU   1,8-diazabicyclo[5.4.0]undec-7-en 
DCC   dicyclohexylcarbodiimide 
DCM   dichloromethane 
DCU   dicyclohexylurea 
DHPE  1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine 
DIC   N,N’-diisopropylcarbodiimide 
DIEA   diisopropylethylamine 
DLS   dynamic light scattering 
DMAP  4-dimethylaminopyridine 
DMF   dimethylformamide 
DMT   dimethoxytrityl 
DNA   desoxyribonucleic acid 
DOPC  dioleoyl-sn-glycero-3-phosphatidylcholine 
DOPE  dioleoyl-sn-glycero-3-phosphoethanolamine 
DPA   dipicolinic acid 




DTT   dithiothreitol 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
122  
EDT   1,2-ethandithiol 
EDTA  ethylenediamin-tetra acetic acid 
EDMA  ethyldimethylamine 
EM   electron microscopy 
ER   endoplasmic reticulum 
ESI   electrospray ionization 
Et3N  triethylamine 
FC   flash chromatography 
Fmoc  fluorenylmethoxycarbonyl 
FRET  Förster resonance energy transfer 
GTP   guanosine-5'-triphosphate 
GUV   giant unilamellar vesicle 
HATU  2-(1H-9-azabenzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV   human immunodeficiency virus 
HOAt  N-hydroxy-9-azabenzotriazole 
HOBt  hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HR-MS  high resolution mass spectrometry 
IR   infrared 
LED   light-emitting diodes 




LUV   large unilamellar vesicles 
m.p.   melting point 
MeOH  methanol 
MLV   multilamellar vesicle 
MS   mass spectrometry 
MTBE  methyl-tert-butylether 
NBD   7-nitro-2-1,3-benzoxadiazol-4-yl 
NCL   native chemical ligation 
NMP   N-methyl-pyrrolidone 
NMR   nuclear magnetic resonance 
NSF   N-ethylmaleimide-sensitive factor 
o/n   over night 
PhiPr  phenylisopropyl 
OG   Oregon Green 
P/L   peptide-to-lipid 
PC   phosphatidylcholine 
PE   phosphatidylethanolamine 
PEG   polyethyleneglycole 
PG   protection group 
PI   phosphoinositide 
pH   potentia hydrogenii 
PNA   peptide nucleic acid 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
POPS  1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L- 
serine 
Pra   propargyl amino acid 
PS   polysterene 




PyAOP  (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate 
PyBOP  (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate 
Rh   lissamine rhodamine B sulfonul 
RNA   ribonucleic acid 
RP   reverse phase 
rt   room temperature 
SNAP  soluble NSF-attachment protein 
SNARE  soluble N-ethylmaleimide-sensitive-factor attachment receptor24 
SPPS  solid phase peptide synthesis 
SPS   solution phase synthesis 
SRB   sulforhodamine B 
ss   single-strand 
SSM   solid-supported membrane 
SUV   small unilamellar vesicle 
Sb   synaptobrevin 2 (VAMP II) 
Syx   syntaxin-1A 
tBu   tret-butyl 
tret   tertiary 
TES   triethylsilane 
TFA   trifluoroacetic acid 
TFMSA Trifluoromethanesulfonic acid 
TFE   trifluoroethanol 
THF   tetrahydrofuran 
TIS   triisopropylsilane 
TLC   thin layer chromatography 




TMS   trimethylsilyl 
Trt   trityl 
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